Literature DB >> 9495732

Surgery for the treatment of overactive bladder.

R A Appell1.   

Abstract

OBJECTIVES: To describe surgical options that may be indicated when conservative management of overactive bladder is unsuccessful.
METHODS: The literature on current endoscopic and open surgical procedures is reviewed.
RESULTS: The endoscopic approach of hydrodistention under anesthesia may be therapeutic, but normally offers only temporary relief of symptoms. Among open surgical procedures, cystolysis has not withstood the test of time and is no longer used. Partial rhizotomy can reduce reflex bladder contractility while preserving other important urogenital functions. Peripheral denervation via a vaginal approach appears effective in as many as 70% of patients with motor instability, but is not effective in interstitial cystitis or other sensory bladder disorders. Transvesical phenol injection is most effective for detrusor instability (DI) caused by multiple sclerosis. Enterocystoplasty is more helpful in intractable DI than in interstitial cystitis. Detrusor myomectomy has yielded excellent results in patients with neurogenic causes of DI. Urinary diversion is rarely required in DI, but may be preferable to enterocystoplasty when severe pelvic pain is present.
CONCLUSIONS: When appropriately chosen, surgical procedures can substantially improve the quality of life of some individuals with overactive bladder.

Entities:  

Mesh:

Year:  1998        PMID: 9495732     DOI: 10.1016/s0090-4295(98)90005-x

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Cystodistension: certainly no standards and possibly no benefits--survey of UK practice.

Authors:  Amita Ashok Mahendru; Hamed Al-Taher
Journal:  Int Urogynecol J       Date:  2009-11-10       Impact factor: 2.894

Review 2.  Extended-release oxybutynin.

Authors:  A M Comer; K L Goa
Journal:  Drugs Aging       Date:  2000-02       Impact factor: 3.923

3.  Oxybutynin extended-release: a review of its use in the management of overactive bladder.

Authors:  M Asif A Siddiqui; Caroline M Perry; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

4.  Transdermal oxybutynin: for overactive bladder.

Authors:  Lynne M Bang; Stephanie E Easthope; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Female neurogenic vesicourethral dysfunction: evaluation and management.

Authors:  Rebecca J McCrery; Rodney A Appell
Journal:  Curr Urol Rep       Date:  2005-09       Impact factor: 2.862

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.